Penumbra, Inc. (NYSE:PEN) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers boosted its holdings in Penumbra, Inc. (NYSE:PEN - Free Report) by 0.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 110,386 shares of the company's stock after acquiring an additional 849 shares during the period. Rhumbline Advisers owned 0.29% of Penumbra worth $26,214,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in PEN. Janus Henderson Group PLC grew its stake in Penumbra by 128.1% in the 3rd quarter. Janus Henderson Group PLC now owns 668,873 shares of the company's stock valued at $129,967,000 after acquiring an additional 375,684 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Penumbra by 3,832.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 368,298 shares of the company's stock worth $71,564,000 after purchasing an additional 358,932 shares during the last quarter. Champlain Investment Partners LLC boosted its stake in shares of Penumbra by 20.6% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,547,972 shares of the company's stock worth $300,786,000 after purchasing an additional 264,122 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in shares of Penumbra during the 3rd quarter worth about $31,965,000. Finally, Braidwell LP boosted its stake in shares of Penumbra by 70.0% during the 3rd quarter. Braidwell LP now owns 361,428 shares of the company's stock worth $70,229,000 after purchasing an additional 148,834 shares during the last quarter. 88.88% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Adam Elsesser sold 15,000 shares of Penumbra stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $242.96, for a total transaction of $3,644,400.00. Following the sale, the chief executive officer now owns 837,582 shares in the company, valued at $203,498,922.72. This trade represents a 1.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Lambert Shiu sold 1,798 shares of the firm's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $242.56, for a total transaction of $436,122.88. Following the sale, the chief accounting officer now directly owns 20,682 shares of the company's stock, valued at $5,016,625.92. The trade was a 8.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,219 shares of company stock worth $4,426,439 over the last 90 days. Company insiders own 5.00% of the company's stock.

Penumbra Trading Down 3.5 %

NYSE PEN traded down $10.60 during mid-day trading on Friday, hitting $292.52. The company's stock had a trading volume of 635,327 shares, compared to its average volume of 492,793. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The stock's fifty day simple moving average is $259.09 and its two-hundred day simple moving average is $228.23. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The firm has a market capitalization of $11.27 billion, a P/E ratio of 860.35, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53.

Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.88 by $0.09. The firm had revenue of $315.52 million for the quarter, compared to analyst estimates of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. Research analysts expect that Penumbra, Inc. will post 3.67 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on PEN. Robert W. Baird raised their price target on shares of Penumbra from $305.00 to $328.00 and gave the stock an "outperform" rating in a research note on Wednesday. Royal Bank of Canada raised their price target on shares of Penumbra from $285.00 to $313.00 and gave the stock an "outperform" rating in a research note on Wednesday. BTIG Research raised their price target on shares of Penumbra from $232.00 to $270.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Oppenheimer initiated coverage on shares of Penumbra in a research report on Tuesday, December 17th. They issued an "outperform" rating and a $275.00 target price on the stock. Finally, Wells Fargo & Company raised their target price on shares of Penumbra from $275.00 to $305.00 and gave the stock an "overweight" rating in a research report on Wednesday. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Penumbra currently has an average rating of "Moderate Buy" and an average price target of $292.64.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.